Why the RTS,S malaria vaccine booster works less well in young African children
Determinants of poor responsiveness to the booster dose of the RTS,S malaria vaccine in African children
This project explores why the RTS,S malaria vaccine's booster gives weaker immune responses in young children living in sub‑Saharan Africa.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11242031 on NIH RePORTER |
What this research studies
If your child is enrolled, the team will collect blood samples to compare antibody, B cell, and T cell responses after the initial vaccine doses and after the booster. They will look at how repeated malaria exposure, other infections, and low micronutrient levels like iron or zinc might change those immune responses. The work combines laboratory studies on patient samples with supporting lab experiments to pinpoint biological reasons for poor booster responses. The goal is to find fixes such as timing changes, nutrition support, or pairing vaccines with prevention measures to make boosters work better.
Who could benefit from this research
Good fit: Ideal candidates are young children (infants up to about 11 years) living in malaria‑endemic parts of sub‑Saharan Africa who have received or are eligible for the RTS,S primary vaccine series and booster.
Not a fit: Adults, people living outside malaria‑endemic regions, or children who never received the initial RTS,S doses are unlikely to be directly involved or benefit from this booster‑focused work.
Why it matters
Potential benefit: If successful, the findings could help make malaria vaccine boosters more effective for children, extending protection and reducing severe malaria.
How similar studies have performed: Previous trials showed that antibody responses to RTS,S boosters are lower than to the primary series and one trial found better protection when RTS,S was paired with repeated chemoprophylaxis, but the precise immune reasons remain unclear.
Where this research is happening
Boston, United States
- Boston University Medical Campus — Boston, United States (Active)
Researchers
- Principal investigator: Valim, Clarissa — Boston University Medical Campus
- Study coordinator: Valim, Clarissa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.